Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease
about
Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease?THE ROLE OF CYSTEINE PROTEASE IN ALZHEIMER DISEASECysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitorsCathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug CandidateStem cell treatment for Alzheimer's diseaseMacrophage derived cystatin B/cathepsin B in HIV replication and neuropathogenesisAPP processing in Alzheimer's diseaseBrain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeuticThe cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activityCysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeuticsGenetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor proteinProteolytic processing of Alzheimer's β-amyloid precursor proteinDeletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AβPP containing the wild-type β-secretase site sequence.Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's diseaseThe protein architecture of human secretory vesicles reveals differential regulation of signaling molecule secretion by protein kinasesIsoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential beta-secretases.Amyloid-β metabolism in Niemann-Pick C disease models and patients.Clues to neuro-degeneration in Niemann-Pick type C disease from global gene expression profilingIdentification and characterization of 3-substituted pyrazolyl esters as alternate substrates for cathepsin B: the confounding effects of DTT and cysteine in biological assays.Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice.An overview of APP processing enzymes and products.Pyroglutamate-amyloid-β and glutaminyl cyclase are colocalized with amyloid-β in secretory vesicles and undergo activity-dependent, regulated secretion.Dysregulation of macrophage-secreted cathepsin B contributes to HIV-1-linked neuronal apoptosis.Proteomics of dense core secretory vesicles reveal distinct protein categories for secretion of neuroeffectors for cell-cell communication.RGD-dependent binding of procathepsin X to integrin alphavbeta3 mediates cell-adhesive properties.Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's diseaseMolecular dynamics to enhance structure-based virtual screening on cathepsin B.Interacting partners of macrophage-secreted cathepsin B contribute to HIV-induced neuronal apoptosis.Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there?Unique neuronal functions of cathepsin L and cathepsin B in secretory vesicles: biosynthesis of peptides in neurotransmission and neurodegenerative disease.Cathepsin B and cystatin B in HIV-seropositive women are associated with infection and HIV-1-associated neurocognitive disorders.Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease.Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters.Aspects of beta-amyloid as a biomarker for Alzheimer's disease.Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease.Biology and pathophysiology of the amyloid precursor protein.Lysosomal fusion dysfunction as a unifying hypothesis for Alzheimer's disease pathology.Protein truncation as a common denominator of human neurodegenerative foldopathies.Cathepsin B as a potential cystatin M/E target in the mouse hair follicle.Insights from molecular modeling into the selective inhibition of cathepsin S by its inhibitor.
P2860
Q21202832-B9DC8544-AFE1-4109-9BCD-011DFC2910E8Q26740104-95519155-44F5-4F43-8651-0E64D6E517A1Q26771736-1EAB9190-57D4-45BD-A884-380A012D2CCEQ26782938-4A52C19D-C3F6-47FA-B545-3C43CF39FDBDQ27007013-2E80BEF1-02F3-49B1-859C-75B735B6F3B5Q27024355-128FA5D9-0C0B-4C14-9616-E70EE7ECC63AQ27694738-6A9E276E-A31F-4726-B651-D84ADB9E8477Q28235248-C23D113B-70AA-4368-AECB-775D22CB866FQ28238581-FB1006A5-F2A4-4CC4-B2FB-ED89399C6D4CQ28240590-1B55F50B-9608-4A0B-964E-9CDEF93ABCE8Q28247574-AEAB8C97-125D-4620-A96B-F687E9A6B771Q28254104-640FB1ED-6C71-470D-A412-98F06D43BBD0Q28259920-2882764D-3D90-4B9B-919A-9AF00D8AE63EQ28285644-605B43D1-1455-487D-B28E-283926ACAAC0Q28482305-51C35038-7D67-4C49-973F-39E0C11E3348Q30319326-26AE00B7-8EE2-47D8-B7D2-6E18222D5344Q31088092-785E60AA-0949-403F-AC9C-DA7B460241A5Q33267280-FC75CF18-9898-492D-B3B8-BA7AA41C971FQ33291906-23232509-23B8-4E5A-A258-8479EB0F5AC2Q33664639-1EDDCA99-9894-4538-BB36-073D4BBC9F61Q33927819-D2596123-9AB3-45EA-8EDD-E6564A778E94Q34076284-225B2984-229E-44A6-9A8E-D7F08A55E186Q34302241-15B3CD00-F64C-4FD9-A2AE-55AB1386B187Q34376138-894865E1-0E47-4DD7-B5EE-C5DFE1775255Q34576631-13AB701E-C53F-4E22-96BA-AB30D9C6E51AQ35596997-A8E87DD4-B9FA-435B-A695-5D7FAD2B9BCBQ35623525-C3096F4E-6D40-4C75-899B-29CFFC82439FQ36259524-AD99A895-0A1F-49D5-9FD3-0746F6E33A78Q36607324-B6C94C4E-4240-49AA-94F6-7914A90CD3D3Q36642766-DF0305B3-204C-459F-9C13-7207F707AE64Q36670527-DF329561-C9F9-49AD-A51E-D68A86DC230CQ37124928-55EEDFCD-ACFB-48A6-AAC1-4BD5B612BF6AQ37346926-507391EF-A165-41A5-A2A3-CEE1018318DCQ37755129-9A36E2B6-17A5-427C-8ED3-9BE26CFBC68DQ37763948-31531D42-5042-4698-BFA4-BCF128B1EC64Q37869935-44366F76-F6B3-42ED-86FC-35E6564786FEQ38042636-3DE349AB-1BB5-401E-9558-D3CD74A5975AQ38091670-C054DA8A-5807-4161-9E5C-D94E00AAB3C9Q38735425-9823AAD4-EA0F-4DB6-80C7-03A5D1647EF3Q38943054-5878B4E2-A30A-4D4E-8427-B1418862DB5C
P2860
Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Inhibition of cathepsin B redu ...... cretase of Alzheimer's disease
@ast
Inhibition of cathepsin B redu ...... cretase of Alzheimer's disease
@en
Inhibition of cathepsin B redu ...... cretase of Alzheimer's disease
@nl
type
label
Inhibition of cathepsin B redu ...... cretase of Alzheimer's disease
@ast
Inhibition of cathepsin B redu ...... cretase of Alzheimer's disease
@en
Inhibition of cathepsin B redu ...... cretase of Alzheimer's disease
@nl
prefLabel
Inhibition of cathepsin B redu ...... cretase of Alzheimer's disease
@ast
Inhibition of cathepsin B redu ...... cretase of Alzheimer's disease
@en
Inhibition of cathepsin B redu ...... cretase of Alzheimer's disease
@nl
P2093
P356
P1433
P1476
Inhibition of cathepsin B redu ...... cretase of Alzheimer's disease
@en
P2093
Doron Greenbaum
Gregory Hook
John Neveu
Katalin F Medzihradszky
Terry Reisine
Thomas Toneff
Vivian Hook
William Lane
P304
P356
10.1515/BC.2005.108
P407
P577
2005-09-01T00:00:00Z